相关临床试验
13
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1934
进行中（未招募）
3
23.1%
已完成
2
15.4%
尚未招募
1
7.7%
招募中
6
46.1%
终止
1
7.7%
暂无批准数据
- Sildenafil, the active ingredient in Viagra, interferes with cancer cells' ability to metastasize by blocking cholesterol access, according to new research from the Weizmann Institute of Science. - The drug traps cholesterol inside cancer cells' recycling compartments, depriving tumors of a critical building block needed for membrane reorganization during invasion and spread. - An observational analysis of 40,000 male cancer patients found those who used sildenafil before diagnosis had better overall survival, with an even stronger association when combined with statins. - Researchers emphasize these findings are preclinical and require clinical trials before sildenafil can be considered for cancer treatment; patients should not self-medicate.
- ImPact Biotech reported that 66% of patients with unresectable locally advanced pancreatic ductal adenocarcinoma became eligible for surgery following treatment with Padeliporfin VTP at the lowest light dose in a Phase 1 trial. - The vascular targeted photodynamic therapy demonstrated a well-tolerated safety profile with no complications related to arterial injury, thrombosis, or other VTP-related morbidity in the initial cohort. - The company is pursuing strategic partnerships for its low-grade upper tract urothelial carcinoma program while advancing the pancreatic cancer indication, which represents a large market opportunity with potential for accelerated regulatory pathway. - Topline data from the Phase 3 ENLIGHTED trial in UTUC and NDA submission are expected in 2026, with additional LA-PDAC Phase 1 results anticipated throughout the year.
- ImmunoBrain will present Phase 1b clinical data for IBC-Ab002, a proprietary anti-PD-L1 monoclonal antibody designed for Alzheimer's disease treatment, at the AD/PD 2026 conference in Copenhagen. - The presentation will include safety, tolerability and biomarker data from the first 40 patients who received four intravenous infusions across five escalating dose cohorts in the IBC-01-01 study. - IBC-Ab002 represents a novel approach using immune checkpoint blockade to activate the peripheral immune system for brain protection and repair in neurodegenerative diseases. - The therapy is based on over 25 years of research showing the brain's dependence on immune system viability for protection and repair mechanisms.
- Evogene, Systasy Bioscience, and LMU University Hospital Munich have formed a EUREKA grant-supported collaboration to develop novel therapies for neutrophil-driven inflammatory diseases, including inflammatory bowel disease. - The partnership leverages Evogene's ChemPass AI™ generative engine for small molecule discovery, Systasy's DNA barcoding technology for neutrophil profiling, and Prof. Klein's clinical insights from rare genetic immunodeficiency research. - The collaboration addresses a significant unmet medical need, as hundreds of millions worldwide suffer from inflammatory diseases where neutrophils play key pathogenic roles but are not directly targeted by existing therapies. - The approach translates Prof. Klein's discovery of a rare genetic condition with reduced neutrophil numbers but preserved immune function into a therapeutic strategy for modulating excessive neutrophil-driven inflammation.
- Researchers at Washington University School of Medicine and Weizmann Institute of Science have successfully adapted CAR-T cell therapy, originally developed for cancer treatment, to target Alzheimer's disease in mice. - The engineered CAR-T cells specifically targeted amyloid beta plaques in the brain, resulting in significant plaque reduction and decreased brain inflammation compared to control treatments. - This represents the first application of CAR-T cell therapy for neurodegenerative diseases and could potentially be adapted for other conditions including ALS and Parkinson's disease. - The study demonstrates improved brain health in treated mice, with reduced activation of microglia and astrocytes following plaque reduction.
- Modulight Biotherapeutics secured $12.2 million in seed financing led by Jibe Ventures and LocalGlobe to develop optogenetic technology for neurological disorders. - The company's platform uses eOPN3, an inhibitory opsin licensed from Weizmann Institute, which stops neural activity when activated by red light to treat pathological electrical circuits. - Trigeminal pain will be the first clinical indication pursued, with the company preparing for FDA pre-IND meetings and anticipating IND-enabling studies completion by 2027. - Preclinical studies demonstrate high efficacy of eOPN3-based treatment in multiple animal models of pain, epilepsy, and movement disorders.
- Tel Aviv University researchers identified a previously unknown molecular mechanism driving ALS progression involving reduced microRNA-126 levels and toxic TDP-43 protein aggregates. - RNA-based gene therapy using microRNA-126 successfully stopped nerve cell degeneration and promoted regeneration in human cells and animal models. - The breakthrough findings reveal that muscle cells normally produce microRNA-126 to regulate TDP-43 protein expression at neuromuscular junctions. - This discovery could serve as the foundation for developing effective treatments for ALS, a fatal neurodegenerative disease affecting millions worldwide.
- Actithera secured exclusive rights to two patent families from Professor Nir London's laboratory at the Weizmann Institute, covering innovative covalent chemistry technologies for radiopharmaceutical applications. - The licensed technologies enable site-specific, durable and traceless protein radiolabeling approaches designed to enhance tumor selectivity and retention in radiopharmaceuticals. - These breakthrough approaches allow radioactivity to be introduced directly into tumor cells by irreversibly and tracelessly radiolabeling tumor-specific proteins while maintaining their native state. - The technologies will be integrated into Actithera's existing discovery platform as the company advances its lead FAP-targeting radioligand candidate toward clinical development.
- ImPact Biotech's first patient in a Phase 1 trial of Padeliporfin VTP therapy for locally advanced pancreatic ductal adenocarcinoma successfully underwent surgical resection after being initially deemed inoperable. - The patient received a single administration of Padeliporfin VTP and subsequently underwent a successful pancreaticoduodenectomy (Whipple procedure) that was not previously considered feasible. - The vascular targeted photodynamic therapy uses intravenous Padeliporfin followed by targeted laser light activation to selectively ablate tumor tissue while preserving healthy structures. - Pancreatic ductal adenocarcinoma represents a significant unmet medical need with only 20% of patients having resectable disease at diagnosis and a five-year survival rate of approximately 10%.
- ImPact Biotech will present updated preliminary results from the ENLIGHTED Phase 3 study evaluating Padeliporfin VTP as a non-invasive treatment option for low-grade upper tract urothelial cancer at AUA 2025. - The company will also share 48-month follow-up data from the PCM-204 Phase 2b trial investigating Padeliporfin VTP for intermediate-risk prostate cancer, expanding on its established mechanism of action in low-risk disease. - Enrollment for the ENLIGHTED trial is expected to complete in the second half of 2025, with the study targeting up to 100 patients across more than 20 clinical sites globally.
